JP2003515558A - 腫瘍を治療するためのメチロール含有化合物の使用 - Google Patents

腫瘍を治療するためのメチロール含有化合物の使用

Info

Publication number
JP2003515558A
JP2003515558A JP2001541496A JP2001541496A JP2003515558A JP 2003515558 A JP2003515558 A JP 2003515558A JP 2001541496 A JP2001541496 A JP 2001541496A JP 2001541496 A JP2001541496 A JP 2001541496A JP 2003515558 A JP2003515558 A JP 2003515558A
Authority
JP
Japan
Prior art keywords
taurolidine
cells
methylol
tumor
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001541496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003515558A5 (enExample
Inventor
ポール カラブレシ
ジェームズ ダルノウスキー
ジェームズ コスティン
Original Assignee
ロード アイランド ホスピタル， ア ライフスパン パートナー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27389609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2003515558(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ロード アイランド ホスピタル， ア ライフスパン パートナー filed Critical ロード アイランド ホスピタル， ア ライフスパン パートナー
Publication of JP2003515558A publication Critical patent/JP2003515558A/ja
Publication of JP2003515558A5 publication Critical patent/JP2003515558A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2001541496A 1999-12-06 2000-12-06 腫瘍を治療するためのメチロール含有化合物の使用 Withdrawn JP2003515558A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16912799P 1999-12-06 1999-12-06
US16912899P 1999-12-06 1999-12-06
US16912299P 1999-12-06 1999-12-06
US60/169,122 1999-12-06
US60/169,128 1999-12-06
US60/169,127 1999-12-06
PCT/US2000/033104 WO2001039763A2 (en) 1999-12-06 2000-12-06 Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors

Publications (2)

Publication Number Publication Date
JP2003515558A true JP2003515558A (ja) 2003-05-07
JP2003515558A5 JP2003515558A5 (enExample) 2008-01-24

Family

ID=27389609

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2001541495A Expired - Fee Related JP5027369B2 (ja) 1999-12-06 2000-12-06 腫瘍を治療する方法
JP2001541496A Withdrawn JP2003515558A (ja) 1999-12-06 2000-12-06 腫瘍を治療するためのメチロール含有化合物の使用
JP2012038079A Expired - Fee Related JP5829948B2 (ja) 1999-12-06 2012-02-24 腫瘍を治療する方法
JP2014153442A Expired - Fee Related JP6234340B2 (ja) 1999-12-06 2014-07-29 腫瘍を治療する方法
JP2016149539A Pending JP2016188244A (ja) 1999-12-06 2016-07-29 腫瘍を治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001541495A Expired - Fee Related JP5027369B2 (ja) 1999-12-06 2000-12-06 腫瘍を治療する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012038079A Expired - Fee Related JP5829948B2 (ja) 1999-12-06 2012-02-24 腫瘍を治療する方法
JP2014153442A Expired - Fee Related JP6234340B2 (ja) 1999-12-06 2014-07-29 腫瘍を治療する方法
JP2016149539A Pending JP2016188244A (ja) 1999-12-06 2016-07-29 腫瘍を治療する方法

Country Status (9)

Country Link
US (6) US6964959B2 (enExample)
EP (3) EP2332542B1 (enExample)
JP (5) JP5027369B2 (enExample)
AT (1) ATE339207T1 (enExample)
AU (2) AU784539B2 (enExample)
CA (3) CA2393159C (enExample)
DE (1) DE60030770T2 (enExample)
ES (2) ES2438535T3 (enExample)
WO (2) WO2001039763A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002363102A (ja) * 2001-04-03 2002-12-18 Ed Geistlich Soehne Ag Fuer Chemische Industrie 新形成細胞の細胞消滅死を誘導する方法
JP2003515557A (ja) * 1999-12-06 2003-05-07 ロード アイランド ホスピタル， ア ライフスパン パートナー 腫瘍を治療する方法
JP2007537200A (ja) * 2004-05-14 2007-12-20 ハンス−ディートリヒ・ポラシェグ タウロリジン製剤及び投与：細菌マイクロフィルム形成に対する治療処置及び抗菌保護
JP2009522347A (ja) * 2006-01-06 2009-06-11 エド・ガイストリッヒ・ゼーネ・アクチェンゲゼルシャフト・フュール・ヒェミッシェ・インドゥストリー 放射線照射された組成物並びにタウロリジン及び／又はタウルルタムを併用する癌の放射線治療
JP2013527224A (ja) * 2010-06-01 2013-06-27 ガイストリヒ・ファーマ・アクチェンゲゼルシャフト 経口薬物療法のための方法および組成物
JP2021535167A (ja) * 2018-08-31 2021-12-16 コーメディクス・インコーポレーテッド 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療
JP2021535173A (ja) * 2018-08-28 2021-12-16 コーメディクス・インコーポレーテッド 若年哺乳動物の身体における神経芽細胞腫を治療するための方法および組成物

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US20060199811A1 (en) * 1997-07-31 2006-09-07 Pfirrmann Rolf W Method of treatment for preventing or reducing tumor growth in the liver of patient
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US20070275955A1 (en) * 1997-07-31 2007-11-29 Ed. Geistlich Soehne Ag Method of treating tumors
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US20030225067A1 (en) * 1999-06-04 2003-12-04 Ruediger Stendel Microdialysis methods and applications for treatment and/or prophylaxis of tumors and/or infections in the central nervous system (CNS) and/or in other parenchymal organs
EP1797884B1 (en) * 1999-12-06 2013-09-11 Geistlich Pharma AG Taurolidine or taurultam for use in the treatment of tumors of the prostate, colon, lung and for the treatment of recurrent glioblastoma multiforme
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
AU779362B2 (en) 2000-10-27 2005-01-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
GB0104383D0 (en) * 2001-02-22 2001-04-11 Psimedica Ltd Cancer Treatment
AU2002252338B2 (en) * 2001-03-15 2007-09-13 Rhode Island Hospital, A Lifespan Partner Taurine compounds
US20080171738A1 (en) * 2001-04-03 2008-07-17 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of Breast Cancer
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
WO2003028642A2 (en) * 2001-10-01 2003-04-10 Rhode Island Hospital, A Lifespan Partner Methods of inhibiting metastases
CA2412012C (en) 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
DE60306828T2 (de) * 2002-03-21 2007-08-02 Ed. Geistlich Söhne AG für chemische Industrie, Wolhusen Vorrichtung für Behandlung eines Tumors im zentralen Nervensystem
RU2353364C2 (ru) * 2002-09-24 2009-04-27 Новартис Аг Применение производных 4-пиридилметилфталазина в производстве лекарственного средства для лечения миелодиспластических синдромов
US7444183B2 (en) * 2003-02-03 2008-10-28 Enteromedics, Inc. Intraluminal electrode apparatus and method
JP5346148B2 (ja) * 2003-03-28 2013-11-20 エー・デー・ガイストリヒ・ゾーネ・アクチェンゲゼルシャフト・フュール・ヒェーミシェ・インダストリー 抗新生物性組成物および治療方法
US20050008684A1 (en) * 2003-07-10 2005-01-13 Claus Herdeis Method of treatment for acne, rosacea and ulcers with taurolidine and/or taurultam in a pharmaceutical composition
CA2482687C (en) * 2003-09-29 2012-11-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
US20080214606A1 (en) * 2004-06-18 2008-09-04 The Government of the United States of America as represented by The Secretary of the Dept. of ..... Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cancer Cells
WO2007010394A2 (en) * 2005-07-19 2007-01-25 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
WO2007020509A1 (en) * 2005-08-15 2007-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth
CA2661409A1 (en) * 2006-09-05 2008-03-13 Myron Spector Method of improving renal function
DE07825069T1 (de) * 2006-09-07 2010-04-08 Ed Geistlich Söhne Ag Für Chemische Industrie Verfahren zur behandlung von knochenkrebs
WO2009102433A2 (en) * 2008-02-11 2009-08-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compounds with mdr1-inverse activity
DE102010010360A1 (de) * 2010-03-05 2011-09-08 Gamptec Gmbh Formulierungen von Taurolidin und Verfahren zu seiner Herstellung
AU2011309832B2 (en) 2010-09-27 2015-01-15 Geistlich Pharma Ag Antimicrobial dental care preparation
WO2013190355A1 (en) 2012-06-18 2013-12-27 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
US20170000778A1 (en) * 2013-12-06 2017-01-05 Emmanuelle di Tomaso Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
JP6863973B2 (ja) * 2015-10-07 2021-04-21 コーメディクス・インコーポレーテッド タウロリジンの皮膚浸透製剤
US20190381060A1 (en) 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
US11541061B2 (en) 2016-01-11 2023-01-03 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
US20190381058A1 (en) * 2016-01-11 2019-12-19 Cormedix Inc. Methods and compositions for treating neuroblastoma in a juvenile mammalian body
CA3010981C (en) * 2016-01-11 2024-09-17 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
WO2018126133A1 (en) * 2016-12-29 2018-07-05 Cormedix Inc. Skin-penetrating formulation of taurolidine
CN109929804B (zh) * 2017-12-15 2020-10-16 天津医科大学肿瘤医院 一种人卵巢癌细胞系及其制备方法和应用
KR20210050544A (ko) * 2018-08-28 2021-05-07 코르메딕스, 인코포레이티드 타우로리딘 가수분해 생성물을 이용한 신경모세포종 치료
WO2020234833A1 (en) 2019-05-22 2020-11-26 Geistlich Pharma Ag Method for treating, preventing, inhibiting or reducing cytokine release
US20220323452A1 (en) 2019-05-22 2022-10-13 Geistlich Pharma Ag Methods and compositions for inhibiting gapdh

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5598170A (en) * 1979-01-18 1980-07-25 Mitsui Toatsu Chem Inc 5-fluorouracil derivative and its preparation
JPH05201878A (ja) * 1991-07-04 1993-08-10 Hawe Neos Dental Dr Hv Weissenfluh Ag 歯周炎処置用医薬製剤
WO1998052572A1 (en) * 1997-05-22 1998-11-26 Oklahoma Medical Research Foundation Use of taurolidine for treatment of leukemias
WO2001039762A2 (en) * 1999-12-06 2001-06-07 Rhode Island Hospital, A Lifespan Partner Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1124285A (en) 1964-10-06 1968-08-21 Geistlich Soehne Ag Novel perhydro-1,2,4-thiadiazine dioxides-(1,1), their preparation and compositionscontaining them
GB1408010A (en) 1972-11-20 1975-10-01 Geistlich Soehne Ag Sulphamoylphenyl-imidazolidinones
GB1557163A (en) 1975-06-24 1979-12-05 Geistlich Soehne Ag Dental care preparations
US4107305A (en) 1975-08-04 1978-08-15 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Treatment of endotoxaemia
GB1588110A (en) 1978-05-31 1981-04-15 Geistlich Soehne Ag Pharmaceutical compositions for the treatment of scars
US4192302A (en) * 1978-09-12 1980-03-11 Boddie Arthur W Hepatic isolation and perfusion circuit assembly
US4337251A (en) 1979-05-09 1982-06-29 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of avoiding and removing adhesions
CA1190855A (en) * 1980-09-03 1985-07-23 Rolf W. Pfirrmann Treatment of osteitis
GB8328074D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compositions
GB8328073D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
GB8328111D0 (en) * 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
US5206352A (en) * 1986-03-28 1993-04-27 Board Of Trustees Of The University Of Illinois Compositions for clones containing DNA sequences associated with multidrug resistance in human cells
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
US5573771A (en) 1988-08-19 1996-11-12 Osteomedical Limited Medicinal bone mineral products
GB8827986D0 (en) * 1988-11-30 1989-01-05 Geistlich Soehne Ag Chemical product
US5819748A (en) 1988-11-30 1998-10-13 Ed Geistlich Sohne Ag Fur Chemische Industrie Implant for use in bone surgery
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
GB9005856D0 (en) 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
GB9015108D0 (en) * 1990-07-09 1990-08-29 Geistlich Soehne Ag Chemical compositions
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
GB9216155D0 (en) * 1992-07-30 1992-09-09 Geistlich Soehne Ag Treatment of dentoalveolar infections
FR2728790B1 (fr) * 1994-12-29 1997-01-24 Cird Galderma Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial
US5954687A (en) 1995-04-28 1999-09-21 Medtronic, Inc. Burr hole ring with catheter for use as an injection port
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
GB9600426D0 (en) * 1996-01-10 1996-03-13 Ed Geistlich Sohne A G Compositions
DE19606897C2 (de) * 1996-02-13 2002-08-29 Geistlich Soehne Ag Mittel zur Verhinderung der Tumorzellverschleppung und der Entstehung von Trokarmetastasen in der offenen und laparoskopischen Chirurgie maligner Tumoren
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
GB9716219D0 (en) 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US6011030A (en) * 1997-09-22 2000-01-04 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating symptoms of microbial infection or sepsis
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
US6117868A (en) 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5598170A (en) * 1979-01-18 1980-07-25 Mitsui Toatsu Chem Inc 5-fluorouracil derivative and its preparation
JPH05201878A (ja) * 1991-07-04 1993-08-10 Hawe Neos Dental Dr Hv Weissenfluh Ag 歯周炎処置用医薬製剤
WO1998052572A1 (en) * 1997-05-22 1998-11-26 Oklahoma Medical Research Foundation Use of taurolidine for treatment of leukemias
WO2001039762A2 (en) * 1999-12-06 2001-06-07 Rhode Island Hospital, A Lifespan Partner Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
JP2003515557A (ja) * 1999-12-06 2003-05-07 ロード アイランド ホスピタル， ア ライフスパン パートナー 腫瘍を治療する方法

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003515557A (ja) * 1999-12-06 2003-05-07 ロード アイランド ホスピタル， ア ライフスパン パートナー 腫瘍を治療する方法
JP2002363102A (ja) * 2001-04-03 2002-12-18 Ed Geistlich Soehne Ag Fuer Chemische Industrie 新形成細胞の細胞消滅死を誘導する方法
JP2007537200A (ja) * 2004-05-14 2007-12-20 ハンス−ディートリヒ・ポラシェグ タウロリジン製剤及び投与：細菌マイクロフィルム形成に対する治療処置及び抗菌保護
JP2012102134A (ja) * 2004-05-14 2012-05-31 Hans-Dietrich Polaschegg タウロリジン製剤及び投与：細菌マイクロフィルム形成に対する治療処置及び抗菌保護
JP2009522347A (ja) * 2006-01-06 2009-06-11 エド・ガイストリッヒ・ゼーネ・アクチェンゲゼルシャフト・フュール・ヒェミッシェ・インドゥストリー 放射線照射された組成物並びにタウロリジン及び／又はタウルルタムを併用する癌の放射線治療
JP2013527224A (ja) * 2010-06-01 2013-06-27 ガイストリヒ・ファーマ・アクチェンゲゼルシャフト 経口薬物療法のための方法および組成物
JP2021535173A (ja) * 2018-08-28 2021-12-16 コーメディクス・インコーポレーテッド 若年哺乳動物の身体における神経芽細胞腫を治療するための方法および組成物
JP7530351B2 (ja) 2018-08-28 2024-08-07 コーメディクス・インコーポレーテッド 若年哺乳動物の身体における神経芽細胞腫を治療するための方法および組成物
JP2021535167A (ja) * 2018-08-31 2021-12-16 コーメディクス・インコーポレーテッド 哺乳動物の身体におけるｍｙｃ発現腫瘍のタウロリジン治療

Also Published As

Publication number Publication date
JP2012136540A (ja) 2012-07-19
WO2001039763A3 (en) 2002-07-11
US6995164B2 (en) 2006-02-07
US20020049200A1 (en) 2002-04-25
JP2014198739A (ja) 2014-10-23
CA2393252A1 (en) 2001-06-07
DE60030770D1 (de) 2006-10-26
WO2001039762A3 (en) 2002-05-02
AU784538B2 (en) 2006-04-27
EP1246617A2 (en) 2002-10-09
US6429224B1 (en) 2002-08-06
EP2332542A2 (en) 2011-06-15
US20030078257A1 (en) 2003-04-24
EP2332542A3 (en) 2011-09-28
CA2696185A1 (en) 2001-06-07
ES2438535T3 (es) 2014-01-17
JP5829948B2 (ja) 2015-12-09
AU2065001A (en) 2001-06-12
US6703413B2 (en) 2004-03-09
ATE339207T1 (de) 2006-10-15
AU2064901A (en) 2001-06-12
ES2531547T3 (es) 2015-03-17
US20030100551A1 (en) 2003-05-29
US20060135513A1 (en) 2006-06-22
WO2001039763A2 (en) 2001-06-07
AU784539B2 (en) 2006-04-27
CA2393159C (en) 2010-04-20
WO2001039762A2 (en) 2001-06-07
JP2003515557A (ja) 2003-05-07
JP2016188244A (ja) 2016-11-04
JP5027369B2 (ja) 2012-09-19
DE60030770T2 (de) 2007-09-06
CA2393159A1 (en) 2001-06-07
CA2696185C (en) 2014-09-23
JP6234340B2 (ja) 2017-11-22
EP1248625A2 (en) 2002-10-16
US6521616B2 (en) 2003-02-18
EP1246617B1 (en) 2006-09-13
US6964959B2 (en) 2005-11-15
EP2332542B1 (en) 2015-02-11
US20020052366A1 (en) 2002-05-02
US20020111345A1 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
JP2003515558A (ja) 腫瘍を治療するためのメチロール含有化合物の使用
US20090163479A1 (en) Use of taurolidine to treat tumors
AU2002252338B2 (en) Taurine compounds
AU2002252338A1 (en) Taurine compounds
EP1797884A2 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071129

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20081031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120126

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120424